# Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

> **NCT01647308** · PHASE2 · TERMINATED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ISIS-APOCIIIRX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01647308
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-03
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study was terminated for business planning purposes. Assessments of APOCIIIRx in this population will be explored in a larger efficacy study
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647308, "Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01647308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*